Calidi Biotherapeutics Reports Q2 2026 Financial Results

What Happened
Calidi Biotherapeutics, Inc. (CLDI) issued a press release on August 13, 2026 announcing its financial results for the quarter ended June 30, 2026 and certain other corporate developments. The company furnished that press release as Exhibit 99.1 to an SEC Form 8‑K (filed Aug 13, 2026). The 8‑K also notes Regulation FD disclosure related to the public release of this information.

Key Details

• Filing date: August 13, 2026 (Form 8‑K).
• Period reported: Quarter ended June 30, 2026 (Q2 2026).
• Press release: Furnished as Exhibit 99.1 to the Form 8‑K; investors should review that exhibit for the specific financial figures.
• Regulatory note: Item 7.01 confirms the company made a public disclosure under Regulation FD when issuing the press release.

Why It Matters
This filing signals that Calidi has publicly released its quarterly operating and financial results; those figures (revenue, net income/loss, cash balances, and any guidance or operational updates) are contained in the press release exhibit. For retail investors, reviewing Exhibit 99.1 is necessary to see the actual earnings and any items that could affect the stock (e.g., changes in cash runway, R&D progress, or corporate actions). The Regulation FD disclosure means the company distributed this material information broadly, so the press release is the authoritative source for the quarter’s results.